相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness
Jingjing Li et al.
ONCOGENE (2020)
OXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidation
Bernd Schoepf et al.
NATURE COMMUNICATIONS (2020)
The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
Keliang Wang et al.
NATURE COMMUNICATIONS (2020)
Global Gene Expression Characterization of Circulating Tumor Cells in Metastasic Castration-Resistant Prostate Cancer Patients
Luis Leon-Mateos et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells
Shikha Gaur et al.
PROSTATE (2019)
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate
Chun-Peng Liao et al.
ONCOGENE (2018)
Monoamine Oxidase Deficiency Causes Prostate Atrophy and Reduces Prostate Progenitor Cell Activity
Lijuan Yin et al.
STEM CELLS (2018)
The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models
Florian Handle et al.
MOLECULAR CANCER THERAPEUTICS (2018)
The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy
Martin Puhr et al.
CLINICAL CANCER RESEARCH (2018)
Agonist-specific Protein Interactomes of Glucocorticoid and Androgen Receptor as Revealed by Proximity Mapping
Joanna K. Lempiainen et al.
MOLECULAR & CELLULAR PROTEOMICS (2017)
MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes Prostate Cancer Metastasis by Engaging Tumor-Stromal Cell Interactions
Jason Boyang Wu et al.
CANCER CELL (2017)
Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer
Jan Kroon et al.
ENDOCRINE-RELATED CANCER (2016)
Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer
Anton M. F. Kalsbeek et al.
AGING-US (2016)
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
John P. M. Finberg et al.
FRONTIERS IN PHARMACOLOGY (2016)
A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2015)
Corticosteroids in the Management of Prostate Cancer: A Critical Review
Chukwuma Ndibe et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2015)
Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme
Axel Heidenreich et al.
EUROPEAN JOURNAL OF CANCER (2014)
Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis
Jason Boyang Wu et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes
Ryan R. Gordon et al.
PLOS ONE (2014)
Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
Yingming Li et al.
CANCER RESEARCH (2013)
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Vivek K. Arora et al.
CELL (2013)
Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: US Food and Drug Administration Drug Approval Summary
Paul G. Kluetz et al.
CLINICAL CANCER RESEARCH (2013)
High mitochondria content is associated with prostate cancer disease progression
Katharina Grupp et al.
MOLECULAR CANCER (2013)
Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205
Martin Puhr et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
Rong Hu et al.
CANCER RESEARCH (2012)
Xenobiotic Metabolism and Disposition in Human Lung Cell Models: Comparison with In Vivo Expression Profiles
Elisabeth Courcot et al.
DRUG METABOLISM AND DISPOSITION (2012)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The psycho gene While the idea of a 'criminal gene' is nonsense, there is growing evidence that some psychopathic behaviour might indeed be grounded in genes
Philip Hunter
EMBO REPORTS (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Elevated monoamine oxidase A levels in the brain - An explanation for the monoamine imbalance of major depression
Jeffrey H. Meyer et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Role of genotype in the cycle of violence in maltreated children
A Caspi et al.
SCIENCE (2002)
Overcoming multidrug resistance in taxane chemotherapy
R Geney et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2002)
Gene expression analysis of prostate cancers
JH Luo et al.
MOLECULAR CARCINOGENESIS (2002)
分享论文
